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Dr Erino Rendina (Rome, Italy). Your results are remarkable,
but the remarkability in terms of AEs also depends on the selection
of your patients. In fact, I think when the patients have an FEV1 of
approximately 50% and no other exclusion criteria, lobectomy
could still be done, and this remains the gold standard because
it’s also preserving the quality of life. Nonetheless, looking specif-
ically at the data you presented here, I agree with your conclusion
that SR can be undertaken safely in high-risk patients with NSCLC
with acceptable 30- and 90-day mortality and morbidity.
In your article, you stated that SR included wedge resection or
segmental resection and could be performed by video-assisted tho-
racic surgery (VATS) or thoracotomy. Potential benefits of thora-
coscopic resections have been reported that include equivalent
oncologic outcomes to those of open surgery and less morbidity.
Do you know what percentage of resections were VATS or open
in your group, and did you look at whether it could have an impact
on the results?The Journal of Thoracic and CarDr Fernando. I’m going to take your first point addressing the
50% FEV1. Our criteria were broad. They included patients who
may have had restrictive disease and cardiac disease. One issue
to point out is that as a surgeon you may see a patient who has
an FEV1 of 45% in whom you would definitely perform a lobec-
tomy, but you may also see a patient with an FEV1 of 55% who
clearly would not tolerate a lobectomy because of other things.
So our criteria were broad, but would still allow the thoracic sur-
geon to look at each patient and make an assessment that SR
was the optimal approach for a specific patient, and allow enroll-
ment in the study.
The second question was with the VATS versus thoracotomy.
Some 65% of these patients in both groups actually had a thoraco-
scopic resection. It was interesting that most of the resections per-
formed were thoracoscopic. I don’t know the breakdown in terms
of wedge and segment, and whether more segments were done
with one approach or the other. That is planned for another analy-
sis. Last year we presented the preliminary data on 150 patients,
looking at 30- and 90-day impact on pulmonary function test,
and we saw no difference between the VATS and open groups in
that particular analysis.
Dr Rendina. You stated that 2 methods of brachytherapy were
allowed in your study. Was your choice to use one method or the
other dictated by any specific reason?
Dr Fernando. This was really at the discretion of the surgeon.
We reviewed the techniques that were out there at the time the
study was developed, and there was no data to support one over
the other. So we left the decision to the surgeon. We have not an-
alyzed the impact of the brachytherapy approach specifically on
complications. There has been a brachytherapy quality control
analysis that was presented at ASTRO by one of the radiation on-
cologists on the protocol, and this looked more at the ability to de-
liver the dose that was planned, and, again, I don’t know the
differences between the 2 groups.
Dr Rendina. Are there particular precautions that have to be
taken with manipulating this material?
Dr Fernando. I wear lead when I do these procedures. When
I’m actually sewing these in place, I don’t tie down directly onto
the lung. I tie extracorporeally when placing these by VATS or
take a clip applier and use the clips as my knot rather than trying
to tie with my hand directly onto the mesh.
Dr Rendina. In your report, the 90-day outcomes demonstrated
a 2.7% mortality, which is absolutely acceptable considering the
greater than average risk of these patients. However, I noticed
that 1 death in the SR group included cancer progression, which
is pretty surprising for patients with stage I disease. Do you have
an explanation for this? Do you want to comment on this issue?
Dr Fernando. I don’t know the results of that. As I said, we’re
planning on presenting the survival and recurrence data when this
matures. I don’t know whether the patient truly had a recurrence or
occult metastatic disease that we didn’t know about at the time,
and the patient presented a month or so after resection with this.
That needs to be looked at a bit more carefully.
Dr Rendina. Thank you.
Dr ThomasWaddell (Toronto, Ontario, Canada). I want to fol-
low up on one point that Dr Rendina made and ask you to talk a bit
about the new study that is going to compare this type of treatment
with SBRT. This morning we heard Dr Puri talk about an analysis,diovascular Surgery c Volume 142, Number 5 1149
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SBRTand surgery were very different. Overall, 7%mortality in the
surgery group and zero in the SBRT group seems to favor SBRT.
So I think that the subject of who should enter these trials is crit-
ical. I take your point that you need to have an accruing trial,
but I think defining what we mean by high risk is very important.
How can we use this information to think about the next trial, that
is, to say how do we define a high-risk person? I would say a 30-
day mortality of 1.4 is not that different than what Dr Allen re-
ported based on Z0030 for lobectomy. So I would come back to
Dr Rendina’s point, that I’m not so sure these patients are really
as high risk as you would have us believe, and certainly they are
not as high risk as the patients who have been up to now dealt
with by SBRT.
Dr Fernando. Actually, I would say that some of those
patients treated with SBRT are probably good-risk patients as
well, who are getting to the radiation oncologists without the
benefit of seeing a surgeon and in some cases may have refused
surgery. Every patient in this study was seen by an ACOSOG-ap-
proved thoracic surgeon, which meant they were board-certified
in cardiothoracic surgery, with 50% of their practice devoted to
thoracic surgery, or members of the General Thoracic Club, and
they had to pass a credentialing test to be involved in this. Every
patient had to be seen by a thoracic surgeon who decided if the
patient was high risk for lobectomy. We can all say that we oper-
ate on patients with an FEV1 of 40% or 35% and sometimes per-
form lobectomies on those patients. Every patient has a specific
set of comorbidities that allows you as a surgeon to make that
judgment. If we had made this trial restrictive and only taken
30% or less or 40% or less, or whatever number we would have
chosen, it would have taken twice as long to accrue to this study.
This next study is going to be looking at patients with exactly the
same set of inclusion criteria. Every patient will have to be seen
by a thoracic surgeon. The only difference is that the tissue diag-
nosis will have to be made up front so we avoid the problem that
other SBRT studies have made by including patients who don’t
have a tissue diagnosis. We are going to have common definitions
of outcome, including complications and recurrence, because
there are also differences in recurrence rates between the SBRT
and surgical studies that can be explained in part by differences
of definition. So this next study will give us our best chance to
see what the role of surgery is for this group of patients.
Dr Todd Demmy (Buffalo, NY). Do you have any data on the
discharge independence of these patients? I think that’s the other
element that we have to capture when we start thinking about com-
parative studies. It was already stated this morning in the lecture
that if it’s less invasive, it tends to win, so SBRT already has an
edge on that. Are you going to collect data to show that these pa-
tients don’t go to nursing homes and end up with a lot of repeat
visits beyond the 90-day mortality end point? Are you going to
look at these functional and quality of life outcomes?
Dr Fernando. With Z4032, we didn’t include that as an end
point, but the Z4099 study, which opened last week, the case report
forms specifically ask those questions about where the patient
goes, home or to an acute care facility. I think that is an important
outcome to measure.
Dr Scott Swanson (Boston, Mass). That was an outstanding
presentation, and you are to be commended for doing this trial1150 The Journal of Thoracic and Cardiovascular Surbecause it’s critical for us as surgeons. The outcome data are amaz-
ing, really good mortality and morbidity.
Do you have any data on lymph node sampling? I know that’s
not the point of this study, but as we go forward comparing with
SBRT, certainly that is a major difference. Was that part of this
study?Was there any requirement?Doyouhave anydetails on that?
Dr Fernando. Lymph node counts were not collected in our
case report forms. We are planning an analysis comparing VATS
and thoracotomy, which Michael Kent from Beth Israel Deaconess
is going to lead. We are going to be looking at all the operative and
path notes that are available as part of the source data, even though
that specific information was not collected in the case report forms
up front. We hope to have that information within the next 6
months to present to everybody when we look at the differences
for the patients who had VATS or thoracotomy.
Dr Servet Bolukbas (Wiesbaden, Germany). During the eval-
uation of your patients, there is a high possibility of detecting
chronic obstructive pulmonary disease. Were there any attempts
to treat those patients with drugs, to send them to pulmonary re-
habilitation to improve FEV1, to switch the patients from high to
normal risk?
Dr Fernando. Not specifically in this group. I think the differ-
ence between these patients and patients in the National Emphy-
sema Treatment Trial study, for example, is that you don’t really
have the luxury of 6 weeks to perform pulmonary rehabilitation
in these patients. You want to try and deal with the cancer within
a reasonable time frame. So we have not been putting patients
through pulmonary rehabilitation before resecting lung cancers.
Dr Bolukbas. But in stage I, I think there is time to do pulmo-
nary rehabilitation for 6 weeks.
Dr Fernando. Perhaps.
Dr Joel Cooper (Philadelphia, Pa). Just for point of emphasis, I
want to recapitulate. I am concerned with people labeling an FEV1
of 50% as defining ‘‘high risk’’ because it’s not, and the pulmonary
physicians and radiotherapists are going to use that definition to in-
dicate that patients are high risk when they are not, and that will
turn influence selection criteria for these trials. Remember, chronic
obstructive pulmonary disease is a couple of pulmonary dis-
eases—airways disease and emphysema, 2 very different condi-
tions, both with very different risk factors. The FEV1 can be
25%with no emphysema because it’s due to small airways disease,
or it can be due to loss of elastic recoil, namely, emphysema. Dif-
fusing capacity is a little different. A person with an FEV1 of 25%
whose computed tomography scan doesn’t show much emphy-
sema and whose diffusing capacity is 35% to 40% is not a particu-
larly high-risk patient for a lobectomy if you choose well. In
summary, FEV1 alone does not adequately define risk for resection
and potentially does a great disservice to patients. Furthermore, it
ignores the importance of the surgeon’s judgment and experience
in selecting appropriate patients for surgical resection.
Dr Fernando. I will say that the American College of Chest
Physicians in their guidelines used 80% for their cutoff for what
defined high or low risk, and they also recommended more inva-
sive evaluation of those patients, including split-lung ventilation/
perfusion scans, which seems kind of ridiculous for patients with
such a high FEV%. That’s something that Frank Detterbeck is in-
vestigating in another study. I also think there is a real problem
with trying to accrue patients to studies, and if we only usedgery c November 2011
Fernando et al General Thoracic Surgerya low FEV1 cutoff point, we would have taken forever to do this,
and perhaps not completed the study.
Dr Joachim Schirren (Wiesbaden, Germany). I have 2 ques-
tions. First, you had a consensus conference about the surgical pro-
cedure from 9 centers? Second, why do you use DLCO? Currently,
I think it’s important to see the dynamics of the patient during spi-
roergometry. The last point is, if you have a patient with a DLCO
that you described, you walk with him, 3 stairs, 4 stairs, and then
you decide if you will operate. It would be interesting to see how
the DLCO was, how the physiologic status was of the patient to
steps, stairs, and, second, to see how the spiroergometry was.
Can you say something about this?
Dr Fernando. We didn’t use a stair-climbing test as such. Ac-
tually, I think it’s 35 sites that participated. The sites listed were the
top 5 accruing sites, plus some of the radiation staff who wereThe Journal of Thoracic and Carinvolved in the study design and implementation. The way the trial
developed is that we had a 2-day conference where we got together
and reviewed what the best literature out there was. We invited
some pulmonologists and radiation oncologists to the meeting as
well. Then we broke off into groups towork out the optimal criteria
that would define a high-risk group, as well as the optimal study for
these patients. So this was worked out some time ago from that
consensus conference. In fact, we used the same criteria for
Z4033, which is the radiofrequency ablation study that also re-
cently completed accrual. The only difference there was that the
surgeon had to see the patient and state that he or she didn’t think
the patient was even a candidate for sublobar resection. As you can
imagine, it took a lot longer to accrue patients to that 50-patient
trial because many of these patients were probably treated with
resection.diovascular Surgery c Volume 142, Number 5 1151
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